Foresite Capital Management VI’s Seaport Therapeutics SPTX Stock Holding History

Foresite Capital Management VI’s Portfolio SPTX Stock Details SPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.7M	Buy	+1,779,521	New	+$31.3M	6.02%	3

Other funds holding SPTX

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TGV

TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Foresite Capital Management VI's SPTX Position: Q2 2026 in Review

Foresite Capital Management VI opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 1,779,521 shares worth $38.7M. The stake represents 6.02% of the portfolio and ranks #3 among its holdings.

54 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

Foresite Capital Management VI held 1,779,521 shares of Seaport Therapeutics worth $38.7M as of Q2 2026.
Seaport Therapeutics was a new Foresite Capital Management VI position in Q2 2026.
Seaport Therapeutics made up 6.02% of Foresite Capital Management VI's portfolio in Q2 2026, its #3 holding.
54 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Foresite Capital Management VI's 13F filing for Q2 2026, filed 14 Aug 2026.